drugset / Trial / NCT05363891

Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis

NCT05363891

Phase 2 Completed 243 enrolled XBiotech, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Phase II, Double-Blind, Placebo-Controlled, Randomized Trial Examining Natrunix in Combination with MTX (+Folate) for the Treatment of Rheumatoid Arthritis

Timeline

Start
2023-08-08
Primary completion
2024-10-31
Completion
2024-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Natrunix Monoclonal antibody 200 mg Subcutaneous
Subject Natrunix Monoclonal antibody 400 mg Subcutaneous

Indications